Deep Track Capital’s Structure Therapeutics GPCR Stock Holding History

Deep Track Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254M	Buy	4,740,072 +460,224	+11%	+$20.4M	3.7%	3
2026 Q1	$206M	Buy	4,279,848 +168,066	+4%	+$11.5M	3.37%	6
2025 Q4	$286M	Sell	4,111,782 -104,029	-2%	-$4.25M	5.1%	4
2025 Q3	$118M	Sell	4,215,811 -918,106	-18%	-$18.3M	3.29%	11
2025 Q2	$106M	Buy	5,133,917 +1,033,917	+25%	+$22.7M	3.41%	11
2025 Q1	$71M	Buy	4,100,000 +1,300,000	+46%	+$31.8M	2.3%	14
2024 Q4	$75.9M	Buy	2,800,000 +1,579,492	+129%	+$56M	2.83%	11
2024 Q3	$53.6M	Buy	1,220,508 +270,508	+28%	+$10.5M	1.7%	22
2024 Q2	$37.3M	Buy	950,000 +909,863	+2,267%	+$37.4M	1.11%	34
2024 Q1	$1.72M	Sell	40,137 -259,863	-87%	-$11M	0.05%	66
2023 Q4	$12.2M	Sell	300,000 -1,615,000	-84%	-$92.6M	0.41%	49
2023 Q3	$96.6M	Sell	1,915,000 -731,782	-28%	-$23.6M	3.73%	9
2023 Q2	$110M	Hold	2,646,782	–	–	5.09%	5
2023 Q1	$63M	Buy	+2,646,782	New	+$62.2M	2.59%	14

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deep Track Capital's GPCR Position: Q2 2026 in Review

Deep Track Capital increased its Structure Therapeutics (GPCR) stake by 11% in Q2 2026, buying an estimated $20.4M and bringing the position to 4,740,072 shares worth $254M. The position accounts for 3.7% of the portfolio, ranked #3.

Deep Track Capital first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $286M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Deep Track Capital held 4,740,072 shares of Structure Therapeutics worth $254M as of Q2 2026.
Deep Track Capital bought 460,224 Structure Therapeutics shares in Q2 2026, an estimated $20.4M.
Structure Therapeutics made up 3.7% of Deep Track Capital's portfolio in Q2 2026, its #3 holding.
Deep Track Capital first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
Deep Track Capital's Structure Therapeutics position peaked at $286M in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.